BCL2 and idiopathic pulmonary fibrosis: Moreover, dasatinib plus quercetin (DQ), which not only targets BCL-2 family members, but also HIF-1α, PI3-kinase and p21-related anti-apoptotic pathways [179], has proved efficient at improving physical dysfunction in idiopathic pulmonary fibrosis (IPF) patients [180].